Literature DB >> 2199532

Bone marrow biopsy in monoclonal gammopathies: correlations between pathological findings and clinical data. The Cooperative Group for Study and Treatment of Multiple Myeloma.

A Riccardi1, G Ucci, R Luoni, A Castello, A Coci, U Magrini, E Ascari.   

Abstract

Between January 1987 and October 1989, 561 consecutive untreated patients with monoclonal gammopathy of undetermined clinical importance (MGUS) (n = 295) or with multiple myeloma (n = 266) were evaluated in a multicentre trial. Both bone marrow biopsy and aspiration (performed at different anatomical sites) were required at presentation. Bone marrow biopsy data indicated that changes in bone marrow composition from MGUS to early multiple myeloma and to advanced multiple myeloma followed a precise pattern, including an increased percentage of bone marrow plasma cells (BMPC%), a shift from plasmocytic to plasmoblastic cytology, an increase in bone marrow cellularity and fibrosis, a change in bone marrow infiltration (becoming diffuse rather than interstitial), a decrease in residual haemopoiesis and an increase in osteoclasts. In multiple myeloma the BMPC% of biopsy specimens and aspirate were closely related, although in 5% of cases the difference between the two values was greater than 20%. Some histological features were remarkably associated with each other. For example, BMPC% was higher in cases with plasmoblastic cytology, heavy fibrosis, or reduced residual haemopoiesis. Anaemia was the clinical characteristic most influenced by bone marrow histology. The BMPC% was the only histological variable which affected the greatest number of clinical and laboratory characteristics, including, besides haemoglobin concentration, erythrocyte sedimentation rate, radiographic skeletal bone disease, and serum concentrations of monoclonal component, calcium, beta 2-microglobulin and thymidine kinase activity. These data indicate that comparative bone marrow histology in monoclonal gammopathies has clinical importance.

Entities:  

Mesh:

Year:  1990        PMID: 2199532      PMCID: PMC502499          DOI: 10.1136/jcp.43.6.469

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  24 in total

1.  Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases.

Authors:  R Bartl; B Frisch; A Fateh-Moghadam; G Kettner; K Jaeger; W Sommerfeld
Journal:  Am J Clin Pathol       Date:  1987-03       Impact factor: 2.493

2.  Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma.

Authors:  B Simonsson; C F Källander; G Brenning; A Killander; A Ahre; J S Gronowitz
Journal:  Br J Haematol       Date:  1985-10       Impact factor: 6.998

3.  Prognostic relevance of cellular morphology in multiple myeloma.

Authors:  E Fritz; H Ludwig; M Kundi
Journal:  Blood       Date:  1984-05       Impact factor: 22.113

4.  Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells.

Authors:  I R Garrett; B G Durie; G E Nedwin; A Gillespie; T Bringman; M Sabatini; D R Bertolini; G R Mundy
Journal:  N Engl J Med       Date:  1987-08-27       Impact factor: 91.245

5.  Prognostic significance of plasma cell morphology in multiple myeloma.

Authors:  A Carter; I Hocherman; S Linn; Y Cohen; I Tatarsky
Journal:  Cancer       Date:  1987-09-01       Impact factor: 6.860

6.  Plasma cell dyscrasia with marrow fibrosis. Clinicopathologic syndrome.

Authors:  L Vandermolen; L Rice; E C Lynch
Journal:  Am J Med       Date:  1985-09       Impact factor: 4.965

7.  Biochemical assessment of bone disease in multiple myeloma.

Authors:  J J Stĕpán; R Neuwirtová; V Pacovský; J Formánková; E Silinková-Málková
Journal:  Clin Chim Acta       Date:  1984-09-29       Impact factor: 3.786

8.  Multiple myeloma: significance of plasmablastic subtype in morphological classification.

Authors:  P R Greipp; N M Raymond; R A Kyle; W M O'Fallon
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

9.  Quantitative histology of myeloma-induced bone changes.

Authors:  A Valentin-Opran; S A Charhon; P J Meunier; C M Edouard; M E Arlot
Journal:  Br J Haematol       Date:  1982-12       Impact factor: 6.998

10.  Importance of quantitative histology of bone changes in monoclonal gammopathy.

Authors:  R Bataille; D Chappard; C Alexandre; P Dessauw; J Sany
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

View more
  5 in total

1.  Argyrophilic nucleolar organizer region counts in multiple myeloma: a histopathological study on bone marrow trephine biopsies.

Authors:  A Pich; L Chiusa; F Marmont; N Cappello; R Navone
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Myelomagenesis: capturing early microenvironment changes.

Authors:  Neha Korde; Irina Maric
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

3.  Outcomes of primary refractory multiple myeloma and the impact of novel therapies.

Authors:  Neil Majithia; S Vincent Rajkumar; Martha Q Lacy; Francis K Buadi; Angela Dispenzieri; Morie A Gertz; Suzanne R Hayman; David Dingli; Prashant Kapoor; Lisa Hwa; John A Lust; Stephen J Russell; Ronald S Go; Robert A Kyle; Shaji K Kumar
Journal:  Am J Hematol       Date:  2015-10-06       Impact factor: 10.047

4.  Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; O Mora; C Tinelli; D Valentini; S Brugnatelli; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; M Giordano; C Delfini; G Nicoletti; C Bergonzi; E Rinaldi; L Piccinini; E Ascari
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

5.  Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; G Ucci; R Luoni; S Brugnatelli; O Mora; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; F Alberio
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.